U.S. markets closed
  • S&P 500

    3,693.23
    -64.76 (-1.72%)
     
  • Dow 30

    29,590.41
    -486.27 (-1.62%)
     
  • Nasdaq

    10,867.93
    -198.88 (-1.80%)
     
  • Russell 2000

    1,679.59
    -42.72 (-2.48%)
     
  • Crude Oil

    79.43
    -4.06 (-4.86%)
     
  • Gold

    1,651.70
    -29.40 (-1.75%)
     
  • Silver

    18.83
    -0.78 (-3.99%)
     
  • EUR/USD

    0.9693
    -0.0145 (-1.47%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • GBP/USD

    1.0857
    -0.0398 (-3.54%)
     
  • USD/JPY

    143.3300
    +0.9950 (+0.70%)
     
  • BTC-USD

    18,989.74
    -66.20 (-0.35%)
     
  • CMC Crypto 200

    434.61
    -9.92 (-2.23%)
     
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • Nikkei 225

    27,153.83
    -159.30 (-0.58%)
     

Pipeline Therapeutics to Participate in the UBS Virtual Biotechnology Private Company Symposium

·1 min read

SAN DIEGO, September 08, 2022--(BUSINESS WIRE)--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will participate virtually in the UBS Biotechnology Private Company Symposium, being held September 21-22, 2022. Pipeline will present a company overview and will conduct virtual one-on-one meetings with investors during the conference.

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials - a SAD/MAD study and a PET study - in healthy volunteers, and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting MS patients.

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005708/en/

Contacts

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com